drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR-T immunotherapy)
drug_description
Patient-derived T cells engineered ex vivo to express a chimeric antigen receptor targeting CD19, then infused intravenously to ablate CD19+ B-lineage cells (naive/memory B cells and plasmablasts), producing B-cell depletion/aplasia and an immune reset.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor recognize CD19 on B-lineage cells and, upon engagement, become activated and kill these cells via cytotoxic mechanisms, producing profound depletion/aplasia of CD19+ B cells and reducing autoreactive B cells and autoantibody production (immune reset).
drug_name
Autologous anti-CD19 CAR-T cells
nct_id_drug_ref
NCT06792344